FINHUB Insights

BAX · Q1 FY26 · Mar 31, 2026

Baxter International Q1 FY26: where the revenue came from and where it went

Baxter International Q1 FY26: revenue $2.7B (+3% year over year). Net profit $0B. Largest cohort Medical Products & Therapies $1.3B. The whole income statement as a sankey diagram from the SEC filing.

Period
Mar 31, 2026
Reported
Apr 30, 2026 10-Q
Sankey diagram of Baxter International's income statement for Q1 FY26: revenue of $2.7 billion splits into segments and flows out into costs, taxes and net profit.

Tap the diagram to enlarge · figures in billions of dollars

Revenue$2.7B +3% year over year
Gross profit$0.9B 33% margin
Operating profit$0.1B 2% margin
Net profit$0B -1% margin

The numbers

All figures in billions of U.S. dollars, for Q1 FY26 (period ends Mar 31, 2026).
ItemValueShare of revenueYear over year
Revenue 2.7 100% +3%
Medical Products & Therapies 1.3 48%
Healthcare Systems & Technologies 0.7 26%
Pharmaceuticals 0.6 22% +7%
Other 0.1 4% +15%
Cost of revenue−1.867%
Gross profit0.933% margin+0pp
Research & development−0.15%+0pp
SG&A−0.727%+0pp
Operating profit0.12% margin+0pp
Interest & other costs−0.1
Net profit0-1%−5pp
Filing on EDGAR More quarters of BAX

Source of the numbers: tables in the filing (10-Q). The diagram is generated automatically and checked against EDGAR before release. How we calculate it → About and methodology.

Older quarters